321 related articles for article (PubMed ID: 38140556)
1. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
[TBL] [Abstract][Full Text] [Related]
2. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection.
Hofmann S; Luther J; Plank V; Oswald A; Mai J; Simons I; Miller J; Falcone V; Hansen-Palmus L; Hengel H; Nassal M; Protzer U; Schreiner S
Microbiol Spectr; 2024 May; 12(5):e0378823. PubMed ID: 38567974
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation.
Zhong Y; Wu C; Xu Z; Teng Y; Zhao L; Zhao K; Wang J; Wang W; Zhan Q; Zhu C; Chen X; Liang K; Cheng X; Xia Y
J Virol; 2022 Nov; 96(21):e0136222. PubMed ID: 36226986
[TBL] [Abstract][Full Text] [Related]
5. Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Interacting with Promyelocytic Leukemia Protein.
Li Y; He M; Gong R; Wang Z; Lu L; Peng S; Duan Z; Feng Y; Liu Y; Gao B
J Virol; 2022 Jul; 96(13):e0054622. PubMed ID: 35695580
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a first-in-class orally available HBV cccDNA inhibitor.
Wang L; Zhu Q; Zhang JD; Zhang Y; Ni X; Xiang K; Jiang J; Li B; Yu Y; Hu H; Zhang M; Wu W; Zeng J; Yan Z; Dai J; Sun K; Zhang X; Chen D; Feng S; Sach-Peltason L; Young JAT; Gao L
J Hepatol; 2023 Apr; 78(4):742-753. PubMed ID: 36587899
[TBL] [Abstract][Full Text] [Related]
7. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
8. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.
Goh ZY; Ren EC; Ko HL
World J Gastroenterol; 2021 Apr; 27(14):1369-1391. PubMed ID: 33911462
[TBL] [Abstract][Full Text] [Related]
9. HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage.
Wang Y; Li Y; Zai W; Hu K; Zhu Y; Deng Q; Wu M; Li Y; Chen J; Yuan Z
Hepatology; 2022 May; 75(5):1275-1288. PubMed ID: 34779008
[TBL] [Abstract][Full Text] [Related]
10. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
11. Heat Shock Protein Family A Member 1 Promotes Intracellular Amplification of Hepatitis B Virus Covalently Closed Circular DNA.
Tang L; An P; Zhao Q; Winkler CA; Chang J; Guo JT
J Virol; 2023 Jan; 97(1):e0126122. PubMed ID: 36519896
[TBL] [Abstract][Full Text] [Related]
12. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
13. [A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment].
Gao L; Mao TH; Peng SW; Wang J; Chen XM; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):99-102. PubMed ID: 35152678
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.
Xia Y; Guo H
Antiviral Res; 2020 Aug; 180():104824. PubMed ID: 32450266
[TBL] [Abstract][Full Text] [Related]
16. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
17. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
18. Mapping the Interactions of HBV cccDNA with Host Factors.
Mohd-Ismail NK; Lim Z; Gunaratne J; Tan YJ
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480501
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the study of hepatitis B virus covalently closed circular DNA.
Ji M; Hu K
Virol Sin; 2017 Dec; 32(6):454-464. PubMed ID: 29280054
[TBL] [Abstract][Full Text] [Related]
20. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach.
Singh P; Kairuz D; Arbuthnot P; Bloom K
World J Gastroenterol; 2021 Jun; 27(23):3182-3207. PubMed ID: 34163105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
